

Solution for haemofiltration, haemodialysis and haemodiafiltration

Educational material for healthcare professionals

Instructions for use

Open the ACCUSOL 35 overpouch from any corner

- Check solution formulation and expiry date
- The ACCUSOL 35 bag may feel damp as a result of the sterilisation process
- Do not carry ACCUSOL 35 by overpouch



Check!

- **ϭ** ACCUSOL 35 is clear and free from particles
- Wings of the bag connector are in open position, never lift the bag with the bag connector
- Short and long-seals are intact (press down on the upper, then lower chambers); ACCUSOL 35 should never be used if either seal is already broken
- ✓ Always use aseptic technique during the whole procedure





Inject prescribed additives

- Remove blue pull-ring and disinfect medication port
- Inject additives
- Additives must be injected before opening the long-seal



Open the long-seal

- Position ACCUSOL 35 with the bag connector facing away from you
- Grasp the two sides of the large chamber
- Squeeze the sides inwards while rolling your wrists under the bag to open the long-seal
- Press down on the upper & lower chambers to complete opening and mixing
- Check that the long-seal has been fully opened
- Recheck that the bag has no leak and is free from particles





5

Open the short seal

- Open the short seal by lifting the large chamber, grabbing the bag firmly in both hands and rolling it toward the connector
- Apply pressure, by leaning over the bag, and pushing the solution towards the short seal to open it
- Check that the short seal has been fully opened
- Recheck that the bag has no leak



Hang ACCUSOL 35

- Remove the cap of the bag connector
- Connect solution line



Start ACCUSOL 35 solution flow


- Hold the bag connector halfway down the wings as per illustration on the following page
- Squeeze until the wings securely clip onto the main body of the connector




IMPORTANT

- The medication port must be disinfected prior to injecting additives
- Additives must be injected before opening the long-seal
- The short and long-seals must be opened before connecting the solution line
- ACCUSOL 35 must be used within 24 hours of mixing
- Do not carry ACCUSOL 35 by overpouch
- Do not lift the bag using the bag connector
- Rarely, precipitation of the solution may occur several hours after the start of therapy and if precipitate is formed, the ACCUSOL 35 solution and CRRT tubing lines must be replaced immediately and the patient carefully monitored











Do not hold the bag connector in this position

	ACCUSOL 35	ACCUSOL 35	ACCUSOL 35
		Potassium 2 mmol/l	Potassium 4 mmol/l
	COMPOSITION (mmol/I)*		
		Upper chamber	
Sodium	129	129	129
Potassium	0	2.67	5.33
Calcium	2.33	2.33	2.33
Magnesium	0.667	0.667	0.667
Chloride	145.7	148.4	151.1
Glucose	0	7.4	7.4
		Lower chamber	
Sodium	173	173	173
Bicarbonate	160	160	160
		Ready to use solution	
Sodium	140	140	140
Potassium	0	2	4
Calcium	1.75	1.75	1.75
Magnesium	0.5	0.5	0.5
Chloride	109.3	111.3	113.3
Bicarbonate	35	35	35
Glucose	0	5.55	5.55
Osmolarity (mOsm/l)	287	296	300
		DESCRIPTION	
Volume	5000 ml	5000 ml	5000 ml
Units per case	2	2	2

- 100% bicarbonate buffer, lactate free
- Different ranges of potassium concentrations with colour coding for clear identification

PM-0070-11/2015-ENG_IRL-3 5

Solution for haemofiltration, haemodialysis and haemodiafiltration

^{*} Converted using formula mol=mass/Relative Atomic Mass Figures based on SmPC

This material does not contain all information.

Please read carefully the SmPC (attached) before prescribing ACCUSOL 35 products. Full and current SmPC can be found on HPRA website www.hpra.ie or can be requested at Nikkiso Belgium byba by e-mail to regulatory@nikkisomedical.com.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via

HPRA Pharmacovigilance, Earlsfort Terrace, IRL-Dublin 2

Tel: +353 1 676 4971, Fax: +353 1 676 2517

Website: <u>www.hpra.ie</u>, E-mail: <u>medsafety@hpra.ie</u>

Suspected adverse reactions should also be reported to Nikkiso Belgium byba by phone on

+32 16 781 770 or by e-mail to complaint@nikkisomedical.com.

